individuals, 18-63 years of age, with at least 18 months of continuous eligibility and a primary care or emergency department visit for LBP. Baseline covariates were captured in in the six-month period prior to their initial LBP diagnosis (index date) and opioid use was captured in the 12-month follow up period. Long-term opioid use was defined as at least 90 days of opioid use. PT and chiropractic were assessed in the 30-day period after index date. Multivariable logistic regression models were estimated to explore the influence of PT and chiropractic care adjusted for patient demographics and comorbidities. Results: 40,929 individuals met inclusion/exclusion criteria. Average age was 41 years, 64.5% were female and 79.9% had commercial health insurance coverage. PT and chiropractic care was used by 5.4% and 5.9% of the sample, respectively. Any opioid use after LBP diagnosis was observed in 54.3% of subjects, 4.4% used opioids long-term. PT was not associated with any opioid use (OR: 1.07; 95% CI: 0.98-1.18) or long-term opioid use (OR: 1.19; 95% CI: 0.97-1.45). Persons who received chiropractic care were less likely to be prescribed an opioid (OR: 0.88; 95% CI: 0.80-0.97) or to use opioids long-term (OR: 0.56; 95% CI: 040-0.77). Conclusions: Utilization of PT or chiropractic care in early management of back pain was low. Chiropractic care but not PT was associated with a lower likelihood of opioid use and long term opioid use.

individuals, 18-63 years of age, with at least 18 months of continuous eligibility and a primary care or emergency department visit for LBP. Baseline covariates were captured in in the six-month period prior to their initial LBP diagnosis (index date) and opioid use was captured in the 12-month follow up period. Long-term opioid use was defined as at least 90 days of opioid use. PT and chiropractic were assessed in the 30-day period after index date. Multivariable logistic regression models were estimated to explore the influence of PT and chiropractic care adjusted for patient demographics and comorbidities. Results: 40,929 individuals met inclusion/exclusion criteria. Average age was 41 years, 64.5% were female and 79.9% had commercial health insurance coverage. PT and chiropractic care was used by 5.4% and 5.9% of the sample, respectively. Any opioid use after LBP diagnosis was observed in 54.3% of subjects, 4.4% used opioids long-term. PT was not associated with any opioid use (OR: 1.07; 95% CI: 0.98-1.18) or long-term opioid use (OR: 1.19; 95% CI: 0.97-1.45). Persons who received chiropractic care were less likely to be prescribed an opioid (OR: 0.88; 95% CI: 0.80-0.97) or to use opioids long-term (OR: 0.56; 95% CI: 040-0.77). Conclusions: Utilization of PT or chiropractic care in early management of back pain was low. Chiropractic care but not PT was associated with a lower likelihood of opioid use and long term opioid use.

groups using generalized estimating equations. Results: The final study sample included 5,768 patients for each treatment group (mean age=66.5 years [SD=11.2]; 66% males). In both Floseal, and Surgiflo Ò groups, approximately 31% of patients required blood transfusions within 0-1 days [odds ratio (OR): 1.04; 95% confidence interval (CI): 0.97-1.11)] and 7% within 2-4 days (OR: 1.02; 95%CI: 0.90-1.16) of surgery. Compared to Floseal, Surgiflo Ò patients had 11% higher ICU admissions (OR: 1.68; 95%CI: 1.56-1.80), longer surgery duration (306 vs. 299 minutes, P,0.05), an average of $2,682 lower hospitalization cost ($44,146 vs. $46,828 P,0.05), and a significantly lower risk of readmission at 30-60-90 days post-discharge (27%, 13% and 12% less likely respectively; all p,0.05). Other outcomes including bleeding, mortality and LOS were comparable (P.0.05). Conclusions: This study included a large sample of patients undergoing cardiovascular surgery over the past 7 years. The results focus on newer hemostatic matrix formulations and suggest relatively comparable clinical outcomes across products. Additionally, these results suggest lower overall hospitalization costs for Surgiflo Ò compared to Floseal.

La enfermedad de Crohn es una afección crónica inflamatoria del tracto gastrointestinal que puede afectar cualquier parte del sistema digestivo, desde la boca hasta el ano. La patogenia de la enfermedad involucra una combinación de factores genéticos, ambientales e inmunológicos que conducen a la inflamación crónica y el daño en el tejido intestinal. Los síntomas pueden variar y pueden incluir dolor abdominal, diarrea, pérdida de peso y fatiga. El diagnóstico se realiza mediante una combinación de herramientas y pruebas diagnósticas, como la colonoscopia, la tomografía computarizada y la resonancia magnética. El tratamiento se centra en el control de los síntomas y puede incluir medicamentos inmunosupresores, cambios en la dieta y el estilo de vida, y en algunos casos, cirugía. El pronóstico puede variar, y las complicaciones pueden incluir obstrucción intestinal, fístulas, abscesos y cáncer de intestino. La investigación continua es importante para mejorar la comprensión y el tratamiento de la enfermedad de Crohn.